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In preclinical models for Duchenne muscular dystrophy, dystrophin restoration during AAV-U7-
mediated exon-skipping therapy was shown to decrease drastically after six months in treated muscles. 
This decline in efficacy is strongly correlated with loss of the therapeutic AAV genomes, probably due 
to alterations of the dystrophic myofiber membranes. To improve the membrane integrity of the 
dystrophic myofibers at the time of AAV-U7 injection, mdx muscles were pre-treated with a single dose 
of peptide-phosphorodiamidate morpholino (PPMO) antisense oligonucleotides that induced temporary 
dystrophin expression at the sarcolemma. The PPMO pre-treatment allowed efficient maintenance of 
AAV genomes in mdx muscles and enhanced the AAV-U7 therapy effect with a ten-fold increase of the 
protein level after six months. PPMO pre-treatment was also beneficial to AAV-mediated gene therapy 
with transfer of micro-dystrophin cDNA into muscles. Therefore, avoiding vector genome loss after 
AAV injection by PPMO pre-treatment would allow efficient long-term restoration of dystrophin and 






The dystrophinopathies are pathologies caused by anomalies in the DMD gene that encodes the sub-
sarcolemmal protein dystrophin. This protein is absent or drastically diminished in Duchenne muscular 
dystrophy (DMD) while it is present but qualitatively and/or quantitatively altered in the Becker 
muscular dystrophy (BMD). The dystrophin structure (central rod-domain made of 24 spectrin-like 
repeats) tolerates large internal deletions (1), which led to the development of two main therapeutic 
strategies: gene therapy with transfer of micro-dystrophin cDNAs in muscles, and targeted exon 
skipping. Both approaches have shown encouraging results using adeno-associated viral (AAV) vectors, 
which allow efficient gene transfer into muscles. AAV-mediated delivery of micro-dystrophins into 
dystrophin-deficient mice has shown remarkable efficiency (2-4) leading to the initiation of an early-
phase clinical trial (5).  
Exon skipping converts an out-of-frame mutation into an in-frame mutation leading to an internally 
deleted but partially functional dystrophin. This therapeutic approach has demonstrated some success 
using antisense oligonucleotides (AONs), but recent studies showed limited clinical benefit (6-9). The 
novel generation of AON chemistries, in particular tricyclo-DNA (tcDNA) (10) and peptide-
phosphorodiamidate morpholino oligonucleotide (PPMO) (11,12), display unprecedented degrees of 
dystrophin restoration in skeletal muscles, but also restore dystrophin expression in the heart and, to a 
lesser extent, in the brain for the tcDNAs. AONs have the enormous advantage of not being 
immunogenic but require regular administration to maintain therapeutic benefit.  
The antisense sequences can be expressed in skeletal or cardiac muscles via a small nuclear RNA such 
as U7snRNA or U1snRNA (13-15). These therapeutic molecules are vectorised in AAV particles, which 
ensure a permanent production of the antisense in dystrophin-deficient murine models (14-16), as well 
as in the dystrophin-deficient dog GRMD (17-19). In all dystrophic models, a one-shot treatment of 
AAV-U7snRNA (AAV-U7) was sufficient to attain substantial levels of restored dystrophin, which is 
associated with a significant improvement of the muscle force (14-16,18,19).  
Despite the high efficiency of AAV-U7 strategy, we recently showed that dystrophin levels decreased 
significantly already after 6 months in various skeletal muscles in the GRMD dog (18) and between 3 
and 12 months in the severely dystrophic dystrophin/utrophin knockout (dKO) mouse (20). This decline 
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in dystrophin was strongly correlated with vector genome loss, most likely due to alterations of the 
dystrophic myofiber membranes. In the context of an AAV-U7 clinical trial for DMD, AAV genome 
fate in dystrophic muscles is of major importance since the vector capsid immunogenicity currently 
limits repeated treatment (21). We recently investigated the vector genome fate in the muscles of the 
moderately dystrophic mdx mouse and showed that non-therapeutic vector genomes were lost quickly 
after the injection and that this loss was diminished when high doses of vector genomes restored 
dystrophin at the sarcolemma (20). Hence, two phases of AAV genome loss occur in dystrophic muscles: 
first, an initial and rapid loss arising after the AAV injection and second, a slow and tardive loss observed 
in the severely dystrophic models, the dKO mouse and the GRMD dog. 
The goal of the present study was to avoid vector genome loss by pre-conditioning the dystrophic 
muscles for AAV injections. First, we demonstrated that therapeutic AAV genomes were lost from mdx 
muscles only during the first phase just after the AAV-U7 injection and not during the following months. 
Moreover, induction of transient high dystrophin expression at the sarcolemma of myofibers with 
peptide-phosphorodiamidate morpholino (PPMO) AONs allowed efficient preservation of AAV 
genomes in mdx muscles. Importantly, the efficacy of AAV-U7-mediated exon skipping as well as 
AAV-mediated micro-dystrophin gene therapy was markedly improved. Therefore, avoiding vector 
genome loss after AAV injection by AON pre-treatment would allow efficient long-term restoration of 
dystrophin in the muscles of DMD patients.  
Considering that more than 80% of DMD mutations are eligible for the personalized medicine involving 
the skipping of a single or of multiple exons (22), this combined therapy approach could in theory benefit 




Therapeutic AAV genomes are lost from mdx muscles after the AAV-U7 injection 
We first investigated the kinetics of maintenance of therapeutic vector genomes in mdx muscles. The 
mdx mouse is a moderately dystrophic mouse model for DMD that carries a nonsense mutation in exon 
23 of the Dmd gene (23). We used an AAV1 vector encoding an U7snRNA, AAV1-U7ex23, to induce 
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efficient exon 23 skipping and therefore dystrophin rescue in mdx muscles (14). This vector (3E+10 
vector genomes (vg)) was injected into three-month-old mdx and wild-type (wt) Tibialis anterior (TA) 
muscles and the number of vector genomes was quantified by quantitative PCR (qPCR) 3, 6, 24 and 39 
weeks post-injection. Three weeks post-injection, ten-fold more vector genomes were quantified in wt 
muscles than in mdx muscles confirming our previous demonstration (20) that the vector genomes are 
drastically lost from the dystrophic muscles during the first three weeks after the AAV injection (Fig. 
1a). Interestingly, the levels of the remaining vector genomes were stable between 3 and 39 weeks post-
injection in both wt and mdx muscles demonstrating that the genome loss occurred mainly in mdx 
muscles before three weeks and not during the following months. 
In mdx muscles, this dose of AAV1-U7ex23 allowed a low exon skipping (around 3% of total dystrophin 
transcripts) at 3 weeks after the injection reaching a plateau (around 45%) by six weeks until the end of 
the experiment (39 weeks) (Fig. 1b). The kinetics of dystrophin synthesis were followed in these mdx 
muscles by western blotting: 3% of normal dystrophin was expressed at 3 weeks, 30% at 6 weeks and 
55% at 24 and 39 weeks (Fig. 1c). In wt muscles, exon skipping level was more than two-fold higher 
than in mdx muscles three weeks post-injection as previously shown (20) and we observed here that a 
similar discrepancy in exon skipping efficiency between the two muscles was maintained over 9 months 
(Fig. 1b). Therefore, the initial loss of vector genomes occurring before three weeks led to a reduced 
exon skipping efficacy in mdx muscles compared to wt muscles and a subsequent restrained dystrophin 
expression level. 
 
AAV genomes are efficiently maintained in Pip6a-PMO rescued mdx muscles  
We then assessed the impact of the presence of dystrophin at the sarcolemma on vector genome 
maintenance in dystrophic muscles. For this, we established a two-step protocol, first dystrophin 
expression was induced temporarily in mdx TA myofibers by a single injection of Pip6a-PMO AON, a 
PPMO that is particularly efficient for mdx exon skipping (11). Then, 1E+11 vg of a non-therapeutic 
AAV carrying non-specific sequence (AAV1-U7scr) that was previously showed to be drastically lost 
after three weeks (20), was injected in the same muscles two weeks after the PPMO injections (Fig. 2a) 
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when dystrophin rescue was already optimal with a mean of 72% of dystrophin-positive myofibers 
(Supplementary data 1).  
As expected, following PPMO pre-treatment and three weeks after AAV1-U7scr injection, 
immunofluorescence analysis revealed a strong dystrophin restoration with appropriate sarcolemmal 
location in mdx injected muscles (Fig. 2b), between 56 to 98% of normal dystrophin levels when 
quantified by western blotting (Fig. 2c), illustrating the high PPMO efficiency for dystrophin restoration. 
The vector genome content was 6 times lower in non-PPMO-treated mdx muscles than in wt muscles, 
as already shown (20). In contrast, the PPMO-treated mdx group had significantly increased numbers of 
vector genomes, with levels exceeding that of wt muscles, although not to significance (Fig. 2d). 
Therefore, a significant dystrophin expression induced by PPMO pre-treatment at the time of AAV1-
U7scr injection protects against the rapid loss of AAV1-U7scr genomes in mdx muscles comparable to 
what was observed in wt muscles. 
 
Pip6a-PMO pre-treatment allows important dystrophin rescue at low dose of therapeutic AAV-
U7ex23  
To evaluate the benefit of an AON pre-treatment on the dystrophin rescue mediated by the therapeutic 
AAV1-U7ex23, Pip6a-PMO AONs were injected into mdx TAs two weeks before injection of a low 
dose of the vector (1E+10 vg) (Fig. 3a), which alone allowed only a weak dystrophin rescue. The benefit 
of AAV1-U7ex23 injection was analysed six months later when dystrophin rescue induced by the single 
PPMO injection was nearly abolished (Supplementary data 1a). Levels of exon 23 skipping analysed by 
nested RT-PCR (Fig. 3b) and quantified by qPCR (Fig. 3c) in mdx TAs treated with AAV1-U7ex23 or 
PPMO alone were low as expected, respectively 9 and 6% of skipped transcripts, leading to the synthesis 
of rescued dystrophin around 2% of the normal level (Fig. 3e). Conversely, TAs treated sequentially 
with PPMOs then with AAV1-U7ex23 showed 54% of skipped transcripts (Fig. 3c) and a dystrophin 
expression at 20% of its normal level (Fig. 3e). Moreover, the vector genome number was 8-fold higher 
in the combined PPMO/AAV1-U7ex23 treated muscles than in AAV1-U7ex23 only injected muscles 
(Fig. 3d). These data demonstrate that the PPMO pre-treatment induced maintenance of the therapeutic 
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U7ex23 genomes in mdx muscles six months after the AAV-U7ex23 injections and remarkably resulted 
in a 10-fold increase of the rescued dystrophin amount.  
 
Pip6a-PMO pre-treatment significantly increases the efficacy of AAV1 mediated micro-
dystrophin gene therapy  
To evaluate the efficacy of an AON pre-treatment on AAV-micro-dystrophin gene therapy, we injected 
Pip6a-PMO AONs into mdx TAs two weeks before the injection of AAV1-MD1 vector (1E+10 vg) 
expressing a murine micro-dystrophin (24) (Fig.4a). Four weeks later, a strong dystrophin restoration 
was observed in PPMO-treated mdx TAs induced by the PPMO pre-treatment (Fig. 4c). The AAV 
genome copy number and micro-dystrophin expression were 3-fold higher in the PPMO/AAV1-MD1 
treated muscles than in AAV1-MD1 only treated muscles (Fig. 4b&c), illustrating the PPMO pre-
treatment benefit on AAV-micro-dystrophin gene therapy. This experiment establishes the proof of 




We previously showed that therapeutic AAV genomes are rapidly lost from dystrophic muscles during 
AAV-U7-mediated exon-skipping therapy (20). However, a strong dystrophin rescue induced by high 
dose of AAV-U7 in mdx muscles prevents this vector genome loss. Here, we showed that from the same 
low dose of AAV-U7 injected in mdx and wild-type muscles, ten-fold more vector genomes were 
maintained in wt muscles than in mdx muscles three weeks after the injections and their levels were 
stable between this time point until the end of the experiment, nine months later in both wt and mdx 
muscles. Therefore, the genome loss occurred principally in mdx muscles before three weeks, when 
dystrophin is not yet present at the sarcolemma, and not during the following months. Hence, in the 
moderately dystrophic mdx muscles, we could observe the initial and rapid AAV genome loss arising 
after the AAV injection and not the slow and tardive loss previously observed in the severely dystrophic 
models, dKO mice and GRMD dogs, where a massive vector genome loss is observable between 3 and 
12 months (18,20). In a second AAV-U7 study performed in GRMD dogs (19), this vector genome loss 
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was not observed certainly because the dogs were followed for 3.5 months and sacrificed before the 
onset of the vector genome loss observed in Vulin et al. (18). 
This difference between the DMD models in term of vector genome loss is certainly due to differences 
in the phenotypic severity of the dystrophin deficient animals. The mdx mouse, which is historically the 
primary animal model for DMD, presents histological signs of muscular dystrophy, but has little muscle 
weakness and relatively normal life span. On the other hand, the dKO mouse suffers from a much more 
severe and progressive muscle wasting, impaired mobility and premature death, similar to DMD patients 
(25,26). GRMD dogs are a larger animal model exhibiting also a severe dystrophic phenotype which 
parallels the human disease with early muscle weakness leading to locomotor, respiratory, digestive and 
cardiac impairments (27). Although mdx mice are mildly affected, they present a peculiar phase of rapid 
cycles of necrosis and regeneration between three and ten weeks of age. Our experiments were 
performed on three-month-old mdx mice, thus the massive initial loss of vector genomes described in 
their muscles cannot be attributed to this severe period of necrosis. 
 
To slow down the loss of therapeutic vector genomes from dystrophic muscles and achieve long-term 
restoration of dystrophin expression, we previously proposed recurrent systemic injections of AONs to 
prevent the progressive reappearance of a dystrophic phenotype caused by the partial loss of AAV 
genomes over time (20). Instead of these successive therapies, we demonstrate here the synergistic 
benefit of the reciprocal treatment combination with first a single AON injection to restore dystrophin 
at the myofiber sarcolemma and secure membrane integrity followed by a single systemic injection of 
AAV-U7 vector to induce a strong and long-lasting expression of dystrophin in muscles. A significant 
dystrophin rescue by PPMO pre-treatment at the time of AAV-U7 injection allows an efficient 
maintenance of the vector genomes in mdx muscles three weeks later. Additionally, this initial 
maintenance of vector genomes increases dystrophin restoration by AAV-U7, around 8-fold at RNA 
level and 10-fold at protein level up to six months later. Of course, this does not rule out our previous 
hypothesis that AON administration subsequent to AAV treatment could supplement AAV-mediated 
dystrophin restoration and act so as to maintain or even increase dystrophin levels, especially as life-
long treatment will be required in DMD patients. We also showed that an AON pre-treatment confers 
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an increased benefit to AAV-mediated micro-dystrophin cDNA transfer into mdx muscles. Indeed, four 
weeks after injection, micro-dystrophin expression was already 3-fold higher in PPMO-treated mdx 
mouse compared to untreated one.  
The PPMO pre-treatment results in substantial dystrophin expression at the time of AAV-U7 injection 
that likely reduces the membrane abnormalities. Once established, an AAV-U7 mediated high 
dystrophin expression will be maintained because it will by itself prevent transgene loss (20). The same 
scenario is conceivable for micro-dystrophin gene therapy. By allowing the maintenance of high vector 
genome content in the decisive period between AAV injection and AAV-mediated transgene expression 
in the treated dystrophic muscles, PPMO-mediated dystrophin restoration guarantees a higher 
therapeutic benefit of the AAV based therapy compared to direct AAV injection. Additionally, in 
condition of poor AAV transduction, especially with systemic delivery some muscles are less transduced 
than others (28), PPMO pre-treatment could help reaching in these muscles the threshold dose of AAV 
genomes needed to restore efficiently dystrophin in mdx muscles. Nevertheless, the PPMO pre-treatment 
will not prevent the tardive vector genome loss observed in the severely dystrophic models but will 
delay significantly its onset by increasing the initial vector genome content in the myofibers. 
The fact that the rescue effect by the pre-treatment on AAV genome maintenance was relatively lower 
for AAV-MD1 (3-fold increase of AAV genome copy number, Fig. 4b) as compared to AAV-U7 
mediated treatment (8-fold increase, Fig. 3d) can likely be explained by the different mechanisms of 
action of the two therapeutic strategies. During AAV-MD1 therapy, the direct transcription and 
overexpression of the micro-dystrophin cDNA result in rapid dystrophin-mediated membrane sealing 
and a minor AAV genome loss. In contrast, the U7-mediated exon skipping is dependent on the U7-
antisense transcription and its action on intrinsically produced dystrophin mRNA which delays 
membrane sealing and thereby favours increased AAV genome loss. Therefore, this strong genome loss 
could be countered more easily by the pre-treatment than the slighter loss observed during AAV-MD1 
therapy. This assumption is consistent with our observation that, following intramuscular injections with 
an equivalent low dose of vectors, AAV-MD1 injected muscles presented a strong dystrophin recue with 
a high percentage of dystrophin-positive fibers (60%) whereas AAV-U7 muscles had little effect at this 
dose (Supplementary data 2). This strong dystrophin rescue by AAV-MD1 was indeed correlated with 
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three times more vector genomes than in AAV-U7 muscles. Finally, this divergence between AAV-
MD1 and AAV-U7 mechanisms of action may explain why in dystrophic dogs robust micro-dystrophin 
expression was obtained for at least two years (29), whereas U7-mediated benefit declined drastically 
after six months (18). 
 
Albeit we can not exclude a lower AAV transduction efficiency in dystrophic muscles compared to 
wild-type tissues, the vector genome loss is certainly due to the fragility of the dystrophic muscle fibers 
that undergo cycles of necrosis/generation as we observed a similar loss of vector genomes in 
cardiotoxin-treated normal muscles (20). It was previously proposed that the poor AAV transduction 
efficiency in mdx muscles could be the result of an exacerbated immune response against the transgene 
product and the AAV capsid that would amplify the cycles of necrosis/generation and leads to the 
transgene elimination (30). 
However, other causes could participate in the process of vector genome loss from the dystrophic 
muscles. Dystrophic myofibers present abnormally leaky membranes that could passively loose the 
vector genomes, as exemplified by the creatine kinase (CK) activity greatly elevated in sera of Duchenne 
patients and preclinical animal models or conversely by Evans blue uptake into dystrophic muscle (31) 
that has been shown to result from permeabilization of the sarcolemma by the abnormal presence of 
connexin hemichannels (32). In addition, AAV vectors were also found associated with exosomes 
termed vexosomes in culture media of AAV producer cells (33). Interestingly, lack of dystrophin at the 
sarcolemma of mdx myofibers was shown to lead to an increased excretion of exosomes that was 
partially restored by dystrophin rescue (34), suggesting that therapeutic vectors might also be lost 
through excretion via exosomes from the dystrophic myofibers. However, such secretion mechanisms 
of AAV vectors remain to be further investigated in vivo. Therefore, AON-mediated dystrophin 
restoration could reduce these membrane abnormalities and thus further preserve the therapeutic vector 
genomes in the dystrophic myofibers. Recently, oxidative damage has been shown to destabilize 
transcripts derived from AAV vectors through free radical damage, reducing the transgene expression 
in dystrophic muscles (35). Interestingly, high expression of micro-dystrophin was able to significantly 
reduce the proportion of oxidized transcripts in GRMD dog muscles showing a direct correlation 
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between the oxidative stress of the myofibers and the dystrophic phenotype. Hence, lowering the 
oxidative status by AON pre-treatment might also facilitate a high AAV transgene expression and help 
reaching the threshold of the therapeutic vector genome number necessary to allow a strong benefit of 
AAV therapies. 
 
The ability to retain vector genomes clearly depends on the efficiency of the AON pre-treatment. Recent 
studies showed limited clinical benefit of 2'OMePS and PMO chemistries (6-9) with a level of restored 
dystrophin observed in patients far too low to protect skeletal myofibers from necrosis. However, the 
novel generation of AON chemistries, in particular the tcDNAs (10) and the PPMOs (11,12), display 
unprecedented level of dystrophin restoration in mice. This new AON generation gives hope to the DMD 
patients and their family and could be good candidates for a pre-treatment for AAV-based therapies. On 
the eve of clinical trials using AAV-based therapies for DMD patients, this study underscores the strong 
impact of combined approaches to improve the benefit of AAV-based therapies allowing the use of 
lower and thus safer vector doses for a larger level of dystrophin expression in the long term.  
 
 
Materials and Methods 
AAV vector production and animal experiments 
A three-plasmid transfection protocol was used with pAAV(U7smOPT-SD23/BP22) (14), 
pAAV(U7smOPT-scr) (20) and codon optimized pΔR4-R23/ΔCT (MD1) (24) plasmids for generation 
of single-strand AAV1-U7ex23, AAV1-U7scr and AAV1-MD1 vectors. Vector titers were determined 
by real-time PCR and expressed as vector genomes per ml (vg/ml). Three-month-old mdx mice were 
injected into the Tibialis anterior (TA) muscles with 1 nmole of Pip6a-PMO oligonucleotides 
(GGCCAAACCTCGGCTTACCTGAAAT) (11). Additionally, 50µl of AAV1-U7scr, AAV1-U7ex23 
or AAV1-MD1 containing 1E+10, 3E+10 or 1E+11 vg were injected into C57BL/6 (wt) or mdx TAs. 
These animal experiments were performed at the Myology Research Center, Paris, France, according to 
the guidelines and protocols approved by the Institutional Review Board. A minimum of four mice were 
12 
 
injected per group for each experiment. At sacrifice, muscles were collected, snap-frozen in liquid 
nitrogen-cooled isopentane and stored at -80°C. 
 
Vector genome quantification 
Genomic DNA was extracted from mouse muscles using the Puregene Blood kit (Qiagen). Copy number 
of AAV genomes and genomic DNA were measured on 100ng of genomic DNA by absolute quantitative 
real-time PCR on a StepOnePlusTM (Applied Biosystems) using the TaqmanR Universal Master Mix 
(Applied Biosystems). Primers (forward: CTCCATCACTAGGGGTTCCTTG and reverse: 
GTAGATAAGTAGCATGGC) and probe (TAGTTAATGATTAACCC) were used to specifically 
amplify the vector genome sequence. As a reference sample, a pAAV plasmid was 10-fold serially 
diluted (from 107 to 101 copies). All genomic DNA samples were analysed in duplicates. 
 
RT-PCR analysis  
Total RNA was isolated from mouse muscle with NucleoSpin® RNA II (Macherey-Nagel), and reverse 
transcription (RT) performed on 200ng of RNA by using the Superscript™ II and random primers (Life 
Technologies). Non-skipped and skipped dystrophin transcripts were detected by nested PCR and 
quantified as described (16).  
 
Western blot analysis 
Protein extracts were obtained from pooled muscle sections treated with 125 mM sucrose, 5 mM Tris-
HCl pH 6.4, 6% of XT Tricine Running Buffer (Bio-Rad), 10% SDS, 10% Glycerol, 5% β-
mercaptoethanol. The samples were purified with the Pierce Compat-Able™ Protein Assay Preparation 
Reagent Set (Thermo Scientific) and the total protein concentration was determined with the Pierce 
BCA Protein Assay Kit (Thermo Scientific). The samples were denatured at 95°C for 5 minutes and 100 
µg of protein were loaded onto Criterion XT Tris-acetate precast gel 3-8% (Bio-Rad). The membrane 
was probed with primary monoclonal antibodies directed against dystrophin (NCL-DYS1, 1:50, Leica 
Biosystems; or MANEX1011B, 1:20, kindly gifted by The Muscular Dystrophy Association 
Monoclonal Antibody Resource (36)) and α-actinin (1:1000, Sigma-Aldrich), followed by incubation 
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with a sheep anti-mouse secondary antibody (horseradish peroxidase conjugated; 1:15000) and Pierce 
ECL Western Blotting Substrate (Thermo Scientific). 
 
Immunohistochemistry 
TA sections of 12 µm were cut and examined for dystrophin expression using the NCL-DYS2 (1:50; 
Leica Biosystems) or MANEX1B (1:50; kindly gifted by The Muscular Dystrophy Association 
Monoclonal Antibody Resource (36)) monoclonal antibodies and a goat anti-mouse secondary antibody 
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Fig. 1. Kinetics of therapeutic vector genome maintenance in mdx muscles. Tibialis anterior (TA) 
muscles of wild-type (wt) and mdx mice were injected with 3E+10 vector genomes (vg) of AAV1-
U7ex23 and the mice were sacrificed 3, 6, 24 and 39 weeks later (3, 6, 24 or 39w). (a) Quantification of 
AAV genomes by absolute Taqman qPCR in injected mdx TAs. AAV genome content is expressed as 
the AAV genome number relative to the value obtained for the mdx muscles injected with AAV1-
U7ex23 at three weeks post-injection. (b) Quantification of exon 23 skipping performed by relative 
TaqMan qPCR and expressed as a percentage of total dystrophin transcripts. (c) Dystrophin restoration 
was evaluated by western blotting with NCL-DYS1 monoclonal antibodies (upper panel) on whole 
protein extracts from the treated muscles (lower panel: α-actinin). The result of one representative TA 
is shown per condition. Dystrophin restoration was quantified by ImageJ software and expressed as the 
percentage of dystrophin expression in wt muscle. The data presented in (a) and (b) represent the mean 
values of three or four TAs per group ± SEM. One of two representative experiments is shown. n.s., 












































































Fig. 2. Effect of dystrophin restoration by Pip6a-PMO pre-treatment on vector genome 
maintenance. (a) TAs from mdx and wt mice were injected with 1 nmole of Pip6a-PMO two weeks 
(-2w) before the injection of 1E+11 vg of the non-therapeutic AAV1-U7scr vector (day 0, d0). Control 
mdx and wt TAs were injected with AAV1-U7scr vector alone. Four TAs were injected per group. The 
mice were sacrificed 3 weeks later (3w). (b) Dystrophin rescue monitored by immunostaining with the 
NCL-DYS2 monoclonal antibody on transverse sections of TA muscles. One representative 
immunostained section is shown per condition. (c) Dystrophin restoration evaluated by western blotting 
with NCL-DYS1 monoclonal antibodies (upper panel) on whole protein extracts from the PPMO-treated 
muscles (lower panel: α-actinin). Dystrophin restoration was quantified by ImageJ software and 
expressed as the percentage of dystrophin expression in wt muscle. (d) Quantification of AAV genomes 
by absolute Taqman qPCR. AAV genome content is expressed as the AAV genome number relative to 
the value obtained for the non PPMO-treated mdx muscles. The data represent the mean values of 4 
muscles per group ± SEM. n. s.: non-significant, ***p < 0.001, Student’s t-test. One of two 























































Fig. 3. Effect of Pip6a-PMO pre-treatment on dystrophin rescue by low dose of AAV-U7ex23. (a) 
Mdx TAs were injected with 1 nmole of Pip6a-PMO two weeks (-2w) before the injection of 1E+10 vg 
of therapeutic AAV1-U7ex23 vector (day 0, d0). Control mdx TAs were injected with PPMO or AAV1-
U7ex23 vector alone. Four TAs were injected per group. The mice were sacrificed 6 months later (6m). 
(b) Level of exon 23 skipping estimated by nested RT-PCR. The 901 bp PCR product corresponds to 
full-length dystrophin transcripts whereas the 688 bp product corresponds to transcripts lacking exon 
23. (c) Quantification of exon 23 skipping performed by relative TaqMan qPCR and expressed as a 
percentage of total dystrophin transcripts. (d) Quantification of AAV genomes by absolute Taqman 
qPCR. AAV genome content is expressed as the AAV genome number relative to the value obtained 
for the non PPMO-treated mdx muscles. The data presented in (c) and (d) represent the mean values of 
the four TAs per group ± SEM. *p < 0.05, ***p < 0.001, Student’s t-test. (e) Dystrophin restoration 
evaluated by western blotting with NCL-DYS1 monoclonal antibodies (upper panel) on whole protein 
extracts from the treated muscles (lower panel: α-actinin). Dystrophin restoration was quantified by 


































































































Fig. 4. Effect of Pip6a-PMO pre-treatment on AAV1 mediated micro-dystrophin gene therapy. 
(a) Mdx TAs were injected with 1 nmole of Pip6a-PMO two weeks (-2w) before injection of 1E+10 vg 
of AAV1-MD1 micro-dystrophin expressing vector (day 0, d0). Control mdx TAs were injected with 
PPMO or AAV1-MD1 vector alone. Five TAs were injected per group. The mice were sacrificed 4 
weeks later (4w). (b) Quantification of AAV genomes by absolute Taqman qPCR. AAV genome content 
is expressed as the AAV genome number relative to the value obtained for the non PPMO-treated mdx 
muscles. The data represent the mean values of the 5 muscles per group ± SEM. *p < 0.05, Student’s t-
test. (c) Expression of PPMO-induced dystrophin (DYS, 427kDa) and micro-dystrophin (µDYS, 
132kDa) evaluated by western blotting with MANEX1011B monoclonal antibodies (upper panel) on 





















































Supplementary data 1. Evaluation of dystrophin restoration by a single Pip6a-PMO 
intramuscular injection. (a) Tibialis anterior (TA) muscles of mdx mice were injected with 1 nmole 
of Pip6a-PMO. Dystrophin expression was evaluated after 2 weeks (2w), 5 weeks (5w), 3 months (3m) 
and 6 months (6m), by western blotting with NCL-DYS1 monoclonal antibodies (upper panel) on whole 
protein extracts from the treated muscles (lower panel: α-actinin). Dystrophin restoration was quantified 
by ImageJ software and expressed as the percentage of wild-type (wt) dystrophin expression. Two 
different muscles were injected per group. (b) Dystrophin rescue was monitored by immunostaining 
with the NCL-DYS2 monoclonal antibody on transverse sections of Pip6a-PMO-injected TA muscles 
2 weeks after injection. One representative immunostained section of four different muscles is shown. 
(c) The percentage of dystrophin positive fibers was quantified by manual count (at least 600 fibers were 
counted). A fiber was considered positive when more than one third of its circumference exhibited a 
staining more intense than negative fibers of untreated mdx TAs. The data represent the mean values of 
4 muscles per group ± SEM. ***p < 0.001, Student’s t-test. 
wt
mdx







































Supplementary data 2. Comparison of AAV1-U7ex23 and AAV1-MD1 therapeutic benefit. Mdx 
TAs were injected with 1E+10 vg of AAV1-U7ex23 or AAV1-MD1 vectors and the mice were 
sacrificed 4 weeks later. Four TAs were injected per group. (a) Dystrophin rescue was monitored by 
immunostaining with the MANEX1B monoclonal antibody on transverse sections of AAV injected TA 
muscles. One representative immunostained section is shown per condition. (b) The percentage of 
dystrophin positive fibers was quantified by manual count (at least 600 fibers were counted). A fiber 
was considered positive when more than one third of its circumference exhibited a staining more intense 
than negative fibers of untreated mdx TAs. (c) Dystrophin restoration evaluated by western blotting with 
MANEX1011B monoclonal antibodies (upper panel) on whole protein extracts from the treated muscles 
(lower panel: α-actinin). (d) Quantification of AAV genomes by absolute Taqman qPCR. AAV genome 
content is expressed as the AAV genome number relative to the value obtained for the AAV1-U7ex23 
mdx muscles.  
The data represent the mean values of 4 muscles per group ± SEM. ***p < 0.001, *p < 0.05, Student’s 
t-test. 
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